Fiche du document
2012
- doi: 10.1111/j.1582-4934.2011.01440.x
- issn: 1582-1838
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1582-4934.2011.01440.x
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/21880113
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1582-4934
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E1CBA8588F2B9
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
P. Nowak-Sliwinska et al., « Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. », Serveur académique Lausannois, ID : 10.1111/j.1582-4934.2011.01440.x
Métriques
Partage / Export
Résumé
Targeted angiostatic therapy receives major attention for the treatment of cancer and exudative age-related macular degeneration (AMD). Photodynamic therapy (PDT) has been used as an effective clinical approach for these diseases. As PDT can cause an angiogenic response in the treated tissue, combination of PDT with anti-angiogenic compounds should lead to improved therapy. This study was undertaken to test the clinically used small molecule kinase inhibitors Nexavar® (sorafenib), Tarceva® (erlotinib) and Sutent® (sunitinib) for this purpose, and to compare the results to the combination of Visudyne®-PDT with Avastin® (bevacizumab) treatment. When topically applied to the chicken chorioallantoic membrane at embryo development day (EDD) 7, a clear inhibition of blood vessel development was observed, with sorafenib being most efficient. To investigate the combination with phototherapy, Visudyne®-PDT was first applied on EDD11 to close all